Negligible real-world evidence exists for later line treatment of multiple myeloma (MM) to assist decisions or reimbursement models, such as episode-based payments.To describe the patterns and clinical/economic outcomes when pomalidomide carfilzomib is used relapsed/refractory MM.A U.S. claims database was identify MM patients with an initial claim (index date) between February 1, 2013, 28, 2015, which assumed be relapse therapy. Treatment regimens were defined all chemotherapy observed...

The aim was to evaluate the impact of a multifaceted set medication management interventions offered by community pharmacy on adherence, health care utilization, and costs within commercial population. Patients initiating therapy 16 drug classes from February 7, 2013, October 6, were various adherence Walgreens pharmacy. linked deterministically IMS medical prescription databases for 6-month pre- post-index data analysis. patients (intervention) matched using other pharmacies (control)...

The Orphan Drug Act of 1983 established incentives for the development drugs that treat rare, or orphan, diseases. We used IMS Health MIDAS database audited biopharmaceutical sales to measure US annual spending on orphan in period 2007–13, and we estimated 2014–18. identified 356 brand-name were approved by Food Administration 1983–2013. While included with both other indications, adjusted include only indications. In 2014 dollars, expenditures totaled $15 billion 2007 $30 2013—representing...

Purpose: To describe patient characteristics and treatment patterns among early initiators of proprotein convertase subtilisin/kexin type nine inhibitors (PCSK9is) who initiated within the first 6 months market availability. Patients methods: This retrospective cohort study used IQVIA's longitudinal open-source point-of-sale pharmacy claims database (LRx) PharMetrics Plus (P+) health plan to identify patients initiating a PCSK9i between January 1, 2016 June 30, 2016. The index date was...

In the United States, incidence of acute myeloid leukemia (AML) has steadily increased over last decade; in 2019, it was estimated that AML would affect 21,450 new patients and lead to 10,920 deaths. Detailed real-world cost estimates comparisons key treatment episodes, such as high-intensity chemotherapy (HIC), low-intensity (LIC), hematopoietic stem cell transplantation (HSCT), relapsed/refractory (R/R), are scarce commercially insured U.S.To examine health resource utilization (HRU),...

Adherence to therapy for pulmonary arterial hypertension is essential optimize patient outcomes, but data on real‐world adherence different drug classes are limited. This retrospective database analysis evaluated relationships between adherence, hospitalization, and healthcare costs in patients treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors. From the IQVIA Adjudicated Health Plan Database, were identified based diagnostic codes prescriptions (ambrisentan,...

To assess adherence and persistence with first-line single-tablet regimen (STR) multi-tablet (MTR) antiretroviral therapy (ART) in newly treated HIV-1 patients.Retrospective analysis of longitudinal pharmacy claims among US patients initiating ART between 1/1/2016 5/31/2016 (index date was defined by first claim for STRs, fill the last MTRs). Adherence assessed over a 12-month period reported as proportion adherent or non-adherent (defined ≤5-day > 5-day gap successive fills, respectively)...

To describe patient characteristics, adherence, and treatment patterns, among adult migraine patients in the United States prescribed erenumab.Migraine is a highly prevalent debilitating disease characterized by recurrent attacks of moderate to severe headache accompanied non-headache symptoms. Erenumab first-in-class calcitonin gene-related peptide receptor (CGRP-R) antagonist indicated for prophylaxis adults.This retrospective longitudinal cohort study used IQVIA's open-source pharmacy...

Delirium is common in ill medical patients. Several drugs and polypharmacy are recognised risk factors, yet little known about drug metabolism people with delirium.The aim of this study was to investigate the activities plasma esterases (drug metabolising enzymes) delirium.This a prospective delirium present at time hospital admission (community acquired) or developing later (hospital patients admitted as emergency aged 75 years over.Following informed consent assent cognitive screening...

BACKGROUND: Antidepressant monotherapy is effective in achieving treatment remission only approximately one third of patients with depression, and even switching to a second antidepressant brings the cumulative rate 50%-55%. This has led an interest augmentation therapy for management treatment-resistant depression. OBJECTIVES: To assess (a) selective serotonin reuptake inhibitor/selective norepinephrine inhibitor (SSRI/SNRI) adherence when augmented second-generation atypical antipsychotics...

This retrospective study estimated healthcare resource use (HRU), symptoms and toxicities (SxTox), costs in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML), stratified by hematopoietic stem cell transplantation (HSCT) status. Claims data were used to identify adult AML diagnoses from 1 January 2008 31 March 2016 the USA. Patients considered R/R if they had an relapse ICD-9 code (205.02) or a line of therapy consistent disease. The final sample (N = 707) included 476 231...

To estimate incremental healthcare resource utilization (HRU) and costs associated with skeletal-related events (SREs) secondary to multiple myeloma (MM), HRU cost differences in patients one vs SREs. Adults MM diagnosis between January 1, 2010-December 31, 2014, benefits coverage ≥12 months pre- ≥6 post-diagnosis were followed last date or December 2015, excluding prior anti-myeloma treatment cancers. SREs identified by procedure codes (pathological fracture, spinal cord compression,...

BackgroundLimited real-world data exist regarding patient carrying compliance and confidence in using different types of epinephrine autoinjectors (EAIs).ObjectiveTo perform a Real-world Assessment Patients' Carrying Time Confidence with Epinephrine Autoinjector Devices (RACE survey).MethodsThis was noninterventional survey patients (≥7 years) who filled 1 or more prescription for Auvi-Q EpiPen between January 2013 2014. Outcomes included proportion their EAI all the time last 7 days...

Although vaccination rates in children exceed 90% the United States, adults are vaccinated at far lower rates. In order to address this issue, additional community immunizers needed, and pharmacists an ideal position fill void.To explore issues barriers related implementation of a pharmacy-based adult vaccine benefit develop recommendations supporting pathway for expansion.A literature review on current environment surrounding vaccinations structured interviews were conducted inform expert...

Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % Canadians suffer from disease. Drugs treating (DRDs) are also known orphan drugs. While is currently developing an drug framework, the United States (US), Orphan Drug Act (ODA) 1983 established incentives for development This study measured total annual expenditure drugs (2007–13) and future...

6582 Background: Prior real-world (RW) studies of advanced non-small cell lung cancer (adv NSCLC) have described overall survival (OS) from diagnosis (Dx) for all patients (pts) as well separately by whether chemotherapy was received. More recently, innovations in systemic anti-cancer treatment (SATx) expanded to include oral targeted agents. Current RW data on OS pts the US are limited, particularly line therapy (LOT). In this study, we use a recent cohort SEER-Medicare examine adv NSCLC Dx...

We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion retrospectively identified 2018 American College Cardiology/American Heart Association guideline very high-risk (VHR) ASCVD criteria; (2) utilization guideline-directed lipid-lowering therapy (LLT); (3) persistent low-density lipoprotein cholesterol (LDL-C) elevations despite statin and/or ezetimibe use.

AbstractAbstractObjective:To evaluate the cost effectiveness of achieving JNC 7 blood pressure goals with angiotensin II receptor blockers (ARBs).Research design and methods:Cost olmesartan, losartan, valsartan, irbesartan was compared real world patient chart claims data from a large US health plan. Patients 18 older ≥2 for an ARB between May 1, 2002 December 31, 2005 were identified database. diagnosis hypertension in 6-month baseline period before first (index) claim ARB-free during...

The Exenatide BID Observational Study (ExOS) was designed to evaluate the clinical effectiveness of exenatide use in patients with type 2 diabetes (T2D) a real-world practice setting United States.Patients were enrolled from 74 sites 9/2007 through 1/2009 and followed for 12 months. primary endpoint achieving or maintaining hemoglobin A1C ≤7.0%, an absolute drop 0.5% baseline. Secondary measures included percentage change baseline variety (lipid markers, weight, BMI, etc.), quality life...

There are limited real-world data comparing cumulative incremental healthcare costs in people living with HIV (PLWH) and those without HIV. This study evaluated all-cause PLWH the US using a matched-cohort design. retrospective, multi-year, cross-sectional analysis annual from 2013 to 2017, projected of age 25 69 years. IQVIA's commercial adjudicated claims database was used identify patients match them (controls). Cumulative were derived health plan-allowed incurred ages 25–69 Undiscounted,...

Aims To evaluate the prevalence and risk factors of migraine progression to assess incremental burden on healthcare systems.Materials methods Adult patients were required have a diagnosis in IQVIA's US adjudicated claims database between 1 January 2012 30 June 2016, continuous enrollment ≥12 months before after index date (i.e. first observed diagnosis), ≥1 additional claim during 12-month post-index period. A previously-developed algorithm identified with prevention-eligible episodic (EM)....

Abstract Background Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. Hypothesis We assessed during 1 year of therapy. Methods This retrospective cohort study used linked laboratory (Prognos) and medical claims (IQVIA Dx/LRx PharMetrics Plus ® ) data. Patients first fill between 7/1/2015 10/31/2019 (index event) ≥ 70 mg/dL were...

Background In the United States, few studies have evaluated geographic variation of severe asthma at subnational level. Objective To assess state-level in prevalence and characteristics persistent States. Methods Patients ≥12 years old with were identified using nationally representative data from IQVIA open-source Medical/Pharmacy Claims PharMetrics Plus® databases (January 2019–December 2020). The index date was defined as patient's earliest qualifying for a diagnosis. Baseline measured...